← Back to Search

Omega-3 Fatty Acid

Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] for Cardiovascular Disease (IPE-PREVENTION Trial)

Phase 4
Waitlist Available
Led By Subodh Verma, MD, PhD
Research Sponsored by Canadian Medical and Surgical Knowledge Translation Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - 3 months post-randomization
Awards & highlights

Summary

This trial tests whether taking icosapent ethyl (IPE), an omega-3 fatty acid, regularly can help people with high heart disease risk and high triglycerides who are already on statins. The study aims to see if IPE can reduce inflammation and improve the function of cells that repair blood vessels. This could help lower the risk of heart problems. Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester, approved in 2012 to reduce triglyceride levels in patients with severe hypertriglyceridemia.

Eligible Conditions
  • Cardiovascular Disease
  • Type 2 Diabetes
  • Cardiovascular Risk
  • High Triglycerides

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - 3 months post-randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - 3 months post-randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the frequency of ALDHhiSSClowCD133+ cells in individuals treated with IPE compared to SOC for 3 months
Secondary outcome measures
20% change in the mean frequency of ALDHhiSSCloCD133+ cells with pro-vascular progenitor cells phenotype in individuals treated with IPE compared to SOC for 3-months.
Stem cells
40% change in the ratio of M1:M2 monocyte precursor cells in individuals treated with IPE compared to SOC for 3-months. M1 monocyte precursor cells defined as ALDHhiSSCmidCD14+CD86+ and M2 monocyte precursor cells defined as ALDHhiSSCmidCD14+CD163+
+1 more
Other outcome measures
Change in the mean frequency of ALDHhiSSChi cells in individuals treated with IPE compared to SOC for 3-months.
Change in the ratio of ALDHhiSSCmid pro-inflammatory:anti-inflammatory monocyte precursor cells in individuals treated with IPE compared to SOC for 3-months.
Changes in the concentration of serum inflammatory markers from baseline to the 3-month visit in individuals treated with IPE compared to SOC
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Icosapent Ethyl + Standard of CareExperimental Treatment1 Intervention
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT
Group II: Standard of CareActive Control1 Intervention
Standard of care therapy (including statin therapy as per inclusion criteria)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
2020
Completed Phase 4
~70

Find a Location

Who is running the clinical trial?

University of Western Ontario, CanadaOTHER
164 Previous Clinical Trials
319,180 Total Patients Enrolled
Unity Health TorontoOTHER
549 Previous Clinical Trials
451,004 Total Patients Enrolled
Canadian Medical and Surgical Knowledge Translation Research GroupLead Sponsor
8 Previous Clinical Trials
869 Total Patients Enrolled
~14 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top